266 publications
Sort by: Date / Relevance
Emicizumab (Hemlibra®) for the prophylactic treatment of bleeding in patients with severe haemophilia A without inhibitors
Zorginstituut Nederland has completed its assessment whether emicizumab (Hemlibra®) for the prophylactic treatment of bleeding in ...
Metreleptin (Myalepta®) for treatment of lipodystrophy
Zorginstituut Nederland has completed its assessment whether metreleptin (Myalepta®) for treatment of lipodystrophy can be ...
Ciclosporin (Ikervis®) for the treatment of severe keratitis in adult patients with the dry eye syndrome
Zorginstituut Nederland has completed its assessment whether ciclosporin (Ikervis®) for the treatment of severe keratitis in ...
Dabrafenib/trametinib (Tafinlar®/Mekinist®) for the adjuvant treatment of adult patients with stage III melanoma
Zorginstituut Nederland has completed its assessment of dabrafenib (Tafinlar®) in combination with trametinib (Mekinist®) for the ...
Explanation of the Interest Form - MEB-ZIN Parallel Procedures pilot
Accelerating patient access to reimbursable innovative medicines has been on the wish list of the government, patient ...
Erenumab (Aimovig®) for the prophylaxis of adults with migraine
Zorginstituut Nederland has completed its assessment whether erenumab (Aimovig®) for the prophylaxis of adults with migraine, can ...
Ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma
Zorginstituut Nederland has completed its assessment whether ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment ...
Venetoclax (Venclyxto®) in combination with rituximab for the treatment of chronic lymphocytic leukaemia (CLL)
Zorginstituut Nederland has completed its assessment whether venetoclax (Venclyxto®) in combination with rituximab for the ...
Lumacaftor/ivacaftor (Orkambi®) for the treatment of cystic fibrosis
Zorginstituut Nederland carried out a marginal assessment in relation to extending the specific conditions for the medicinal ...
Tezacaftor/ivacaftor (Symkevi®) with ivacaftor monopreparation (Kalydeco®) for the treatment of cystic fibrosis
Zorginstituut Nederland carried out an assessment in relation to extending the specific conditions for the medicinal product ...